Combining SBRT with PD-1 Blockade for Metastatic Kidney Cancer
Official title: Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study
Run by Nanfang Hospital, Southern Medical University · NCT06327178 · Data updated 2026-11-12
This study is testing if combining a type of targeted radiation therapy with a new immune treatment can help people with advanced kidney cancer feel better and have fewer side effects.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | October 1, 2023 |
| Main results expected | April 30, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | May 25, 2025 |
| Trial ID | NCT06327178 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with advanced stage IV renal cell carcinoma who have previously received SBRT and PD-1 blockade treatment.
✕Probably not a fit
Patients with additional malignancies that are progressing or require active treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the systemic anti-tumor activity and safety of combining stereotactic body radiotherapy (SBRT) with concurrent PD-1 blockade in patients with metastatic clear renal cell carcinoma. The study focuses on assessing the objective response rate in non-irradiated lesions and monitoring the incidence of adverse events. By exploring the abscopal effects of SBRT, the research seeks to enhance the understanding of immune responses triggered by this treatment combination.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with metastatic kidney cancer by enhancing systemic immune responses.
How similar studies have gone: Previous studies have shown promising results with similar combinations of radiotherapy and immune checkpoint inhibitors, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age≥18 years at the time of signing informed consent; * Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8); * Previously received SBRT and concurrent PD-1 blockade treatment； * Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria. Exclusion Criteria: * Patients who cannot be adequately followed up; * Has a known additional malignancy that is progressing or requires active treatment.
Where it's running
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Guozhu Xie
- Email: xieguozhu@126.com
- Phone: 02062787693
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.